Switzerland's medical products authority has granted the first approval for a malaria medicine designed for small infants, touted as an advance against a disease that takes hundreds of thousands of lives — nearly all in Africa — each year.
Swissmedic gave a green light Tuesday for the medicine from Basel-based pharmaceutical company Novartis for the treatment of babies with body weights between 2 and 5kg, which could pave the way for hard-hit African nations to follow suit in the coming months.
